Lento Bio was formed in 2022 in partnership with Ichor Life Sciences and Clarkson University, with the goal to develop effective, safe, and durable treatments for chronic age-related disease by using small molecules to directly target molecular damage.
Location: United States, New York, Village of Potsdam
Employees: 1-10
Founded date: 2022
Investors 1
| Date | Name | Website |
| 05.07.2025 | Kayak Vent... | kayak.vent... |
Mentions in press and media 3
| Date | Title | Description |
| 03.06.2024 | Lento Bio Relocates to Syracuse, NY, Joining Ichor Life Sciences' New Biotech Incubator Facility | The move will increase access to key resources for Lento Bio as the company expands its preclinical development operations SYRACUSE, NY, USA, June 3, 2024 /EINPresswire.com/ -- Lento Bio, a preclinical pharmaceutical startup focused on deve... |
| 07.02.2023 | Lento Bio Announces Official Scientific Collaboration with Florida State University and Expansion of Advisory Board | Medicinal Chemistry Collaborator Dr. James Frederich, Assistant Professor at FSU Collaboration focuses on medicinal chemistry and will help accelerate lead asset development, with board expansion focused on well-rounded scientific expertise... |
| 06.06.2022 | Lento Bio, An Ichor Life Sciences Portfolio Company, Launches with Aims to Develop Anti-Glycation Drugs for Presbyopia and Diseases of Aging | POTSDAM, NY / ACCESSWIRE / June 6, 2022 / Lento Bio, Inc., a preclinical pharmaceutical company focused on developing small-molecule therapeutics to target molecular damage driving age-related disease, announced its launch today. The compan... |